Medroxyprogesterone
- Half-Life (t½)
- PO: 50h · IM: 50h
- Formula
- C22H32O3
- Molecular Weight
- 386.52 g/mol
- Aliases
- Provera, Depo-Provera, MPA, medroxyprogesterone acetate
Pharmacological Mechanism
Synthetic progestin (17α-hydroxyprogesterone derivative). Agonizes the progesterone receptor; suppresses pituitary LH/FSH to inhibit ovulation, thickens cervical mucus, transforms endometrium. Oral (HRT/amenorrhea/oncology) + IM depot (q3-month contraception).
Half-Life & Elimination Curve (PO: 50h · IM: 50h)
Plasma (PO)t½ Decay (50h)
- 0×t½0h100% (4.38 µg/L)
- 1×t½50h50% (2.19 µg/L)
- 2×t½4.2d25% (1.09 µg/L)
- 3×t½6.3d12.5% (0.547 µg/L)
- 4×t½8.3d6.3% (0.274 µg/L)
- 5×t½10.4d3.1% (0.137 µg/L)
Dosing Guidelines
- Oral (PO): Typical 5 mg (Range: 2.5–10 mg)
- Intramuscular (IM): Typical 150 mg
Pharmacokinetic Parameters
- Oral (PO): Bioavailability (F): 90% · Volume of Distribution (Vd): 1000 L · Absorption (ka): 2.64 h⁻¹ (t½ka ≈ 16m) [PMID 2943134]
- Intramuscular (IM): Bioavailability (F): 100% · Volume of Distribution (Vd): 1000 L [PMID 2943134]
Target Organ Systems
- Endocrine System
- Reproductive System
Chemical Structure & Identifiers
- InChIKey: FRQMUZJSZHZSGN-HBNHAYAOSA-N
- SMILES: C[C@H]1C[C@@H]2[C@H](CC[C@]3([C@H]2CC[C@@]3(C(=O)C)O)C)[C@@]4(C1=CC(=O)CC4)C
References